BR112013023092A2 - mirra em uma forma de dosagem vaginal - Google Patents

mirra em uma forma de dosagem vaginal

Info

Publication number
BR112013023092A2
BR112013023092A2 BR112013023092A BR112013023092A BR112013023092A2 BR 112013023092 A2 BR112013023092 A2 BR 112013023092A2 BR 112013023092 A BR112013023092 A BR 112013023092A BR 112013023092 A BR112013023092 A BR 112013023092A BR 112013023092 A2 BR112013023092 A2 BR 112013023092A2
Authority
BR
Brazil
Prior art keywords
myrrh
dosage form
vaginal
vaginal dosage
treatment
Prior art date
Application number
BR112013023092A
Other languages
English (en)
Inventor
Eva Brandt
Original Assignee
Sonia Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/050,225 external-priority patent/US8287924B2/en
Priority claimed from EP11158593.1A external-priority patent/EP2500026B1/en
Application filed by Sonia Pharma Gmbh filed Critical Sonia Pharma Gmbh
Publication of BR112013023092A2 publication Critical patent/BR112013023092A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

resumo tratamento de atrofia vaginal como nova para mirra a invenção refere-se a uma nova indicação da mirra, ou seja, o tratamento da atrofia vaginal como sintoma da menopausa. a invenção refere-se ainda a uma preparação farmacêutica em uma forma de dosagem vaginal para o tratamento da atrofia vaginal e a um método para a preparação de uma preparação farmacêutica contra atrofia vaginal como sintoma da menopausa.
BR112013023092A 2011-03-17 2012-03-15 mirra em uma forma de dosagem vaginal BR112013023092A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/050,225 US8287924B2 (en) 2011-03-17 2011-03-17 Treatment of menopausal symptoms as novel indication for myrrh
EP11158593.1A EP2500026B1 (en) 2011-03-17 2011-03-17 Treatment of menopausal symptoms as novel indication for myrrh
PCT/EP2012/054548 WO2012123539A1 (en) 2011-03-17 2012-03-15 Treatment of vaginal atrophy as novel indication for myrrh

Publications (1)

Publication Number Publication Date
BR112013023092A2 true BR112013023092A2 (pt) 2016-12-06

Family

ID=45929506

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013023092A BR112013023092A2 (pt) 2011-03-17 2012-03-15 mirra em uma forma de dosagem vaginal

Country Status (8)

Country Link
JP (1) JP5519879B2 (pt)
KR (1) KR20130130034A (pt)
AU (1) AU2012228213B2 (pt)
BR (1) BR112013023092A2 (pt)
CA (1) CA2829792C (pt)
CO (1) CO6771460A2 (pt)
MX (1) MX352788B (pt)
WO (1) WO2012123539A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2967506A1 (en) 2016-01-18 2017-07-18 Nadiah Abdulkarim A. Alessa Composition for treatment and preventative of the human papilloma virus hpv infection, ulcerations and boils
WO2020006191A1 (en) * 2018-06-29 2020-01-02 The Procter & Gamble Company Vaginal care compositions
DE112020006124T5 (de) * 2019-12-15 2022-12-08 Banooye Armaghan Teb Pflanzliche Zusammensetzungen und Verabreichungsverfahren zur Behandlung von Infektionen und Entzündungen der vulvovaginalen und der Beckenorgane

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4592912A (en) 1983-10-31 1986-06-03 Harriet Nickolaus Ache and pain relieving and preventing composition
US4719111A (en) 1985-06-14 1988-01-12 Wilson Lynn M Novel composition for treatment of decubitus ulcers
JPS63104924A (ja) * 1986-10-20 1988-05-10 Kanebo Ltd 膣坐剤
AU630561B2 (en) 1990-06-12 1992-10-29 Cathy Palou A therapeutic preparation containing myrrh for treating skin disorders
US6350784B1 (en) * 1996-02-12 2002-02-26 Meryl J. Squires Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases
US5248503A (en) 1992-01-03 1993-09-28 Emanuel King Rosalba Herbal dietary supplement
US6077513A (en) 1996-05-02 2000-06-20 Massoud; Ahmed Mohamed Ali Drug for treatment of bilharziasis (Schistosomiasis)
ZA200000192B (en) * 1998-10-30 2000-08-07 Jullienne Jacques Roger Jean M Novel composition.
US6893648B2 (en) 2002-01-04 2005-05-17 Harold Mermelstein Composition and method for treatment of vaginal dryness
CN1559586A (zh) * 2004-03-04 2005-01-05 健 曹 一种治疗妇科疾病的外用中成药
CN1679687A (zh) 2005-02-02 2005-10-12 姚素英 一种治疗妇科疾病外用胶囊及制备方法
CN101057892B (zh) * 2006-04-19 2010-11-10 河南省宛西制药股份有限公司 一种治疗阴道疾病的药物组合物及其制备方法和应用
CN101849981B (zh) * 2010-06-22 2011-11-23 南京中医药大学 一种具有抗妇科肿瘤作用的没药有效部位及其制备方法和其应用

Also Published As

Publication number Publication date
MX2013010415A (es) 2013-12-02
AU2012228213A1 (en) 2013-09-12
JP5519879B2 (ja) 2014-06-11
MX352788B (es) 2017-12-05
JP2014508158A (ja) 2014-04-03
CO6771460A2 (es) 2013-10-15
WO2012123539A1 (en) 2012-09-20
AU2012228213B2 (en) 2015-08-06
KR20130130034A (ko) 2013-11-29
CA2829792C (en) 2017-04-04
CA2829792A1 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
GB201118656D0 (en) New compounds
UA106634C2 (uk) Тверда фармацевтична дозована форма
PH12014501984A1 (en) Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor
MX366899B (es) Nuevos compuestos.
ECSP12012310A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
MX349004B (es) Nuevos compuestos.
UY34918A (es) Nuevos ácidos 5-aminotetrahidroquinolin-2-carboxílicos y su uso
MX346224B (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
HN2010002518A (es) Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
BR112016021648A2 (pt) novos compostos
PH12016501965A1 (en) S1p modulator immediate release dosage regimen
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
ES2524385R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
AR091706A1 (es) Formulaciones de laquinimod sin agentes alcalinizantes
EP2818172A4 (en) TLR4 MEDIUM, TISSUE HOMEOSTAT, HEPATOCYTE GROWTH FACTOR INDUCTOR, TISSUE-DISAPPEARING AGENT, AND SIRTUINE INDUCTOR WITH HYALURONIC ACID FRAGMENTS AS ACTIVE AGENTS THEREOF
BR112015000616A2 (pt) tratamento da esclerose múltipla com combinação de laquinimode e fampridina
MX2016006603A (es) Compuestos piperidinicos con actividad multimodal contra el dolor.
BR112013020359B8 (pt) Colágeno gelificável e meios para a sua provisão
BR112015013106A2 (pt) uso de extrato de feno-grego para melhorar a libido feminina
BR112016021656A2 (pt) inibidores das vias de sinalização de wnt
BR112013023092A2 (pt) mirra em uma forma de dosagem vaginal

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL